$TEVA 8-K SEC Filings

Filed On	Filing
16 Sep 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation Creating the series of Securities (as defined herein) designated
14 Sep 2026	8-K: Other Events On September 14, 2026, Teva Pharmaceutical Industries Ltd. (the “Company”) began trading its ordinary shares on the New York Stock Exchange, in lieu of its American depositary shares (“ADSs”), under the same ticker symbol under which the...
11 Sep 2026	8-K: Regulation FD Disclosure; Other Events To: the other Euro Underwriters (as defined herein) listed in Part A of Schedule I hereto;
03 Sep 2026	8-K: Other Events
03 Sep 2026	8-K: Material Modification to Rights of Security Holders
29 Jul 2026	8-K: Results of Operations and Financial Condition
28 May 2026	8-K: Submission of Matters to a Vote of Security Holders
29 Apr 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
28 Jan 2026	8-K: Results of Operations and Financial Condition
12 Jan 2026	8-K: Results of Operations and Financial Condition
11 Dec 2025	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
05 Nov 2025	8-K: Results of Operations and Financial Condition
30 Jul 2025	8-K: Results of Operations and Financial Condition
05 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
28 May 2025	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
22 May 2025	8-K: Regulation FD Disclosure; Other Events
07 May 2025	8-K: Results of Operations and Financial Condition
29 Jan 2025	8-K: Results of Operations and Financial Condition
12 Nov 2024	8-K: Departure/Election of Directors or Officers; Compensation
06 Nov 2024	8-K: Results of Operations and Financial Condition

Comments